Celadon Partners-backed GeneFab, a laboratory information management platform, agreed to acquire chemistry, manufacturing, and controls capabilities from Senti Biosciences, a developer of a programmable biology platform for cancer therapies, for $38m. “The formation of GeneFab is an exciting step forward to accelerate the design, development and manufacturing of innovative genetic medicines. Our unique capabilities enable us to provide specialized synthetic biology and manufacturing expertise to a wide range of cell and gene therapy companies. As an extension of our customers' teams, we believe that our advanced capabilities and expertise will enable the translation of scientific innovation into tangible treatments, and help our customers bring life-changing therapies to patients in need,” Dr. Lee, GeneFab CEO.